119 related articles for article (PubMed ID: 29355526)
21. Immunoproteasome in cancer and neuropathologies: a new therapeutic target?
Bellavista E; Andreoli F; Parenti MD; Martucci M; Santoro A; Salvioli S; Capri M; Baruzzi A; Del Rio A; Franceschi C; Mishto M
Curr Pharm Des; 2013; 19(4):702-18. PubMed ID: 23016859
[TBL] [Abstract][Full Text] [Related]
22. Horner-Wadsworth-Emmons approach to piperlongumine analogues with potent anti-cancer activity.
Han LC; Stanley PA; Wood PJ; Sharma P; Kuruppu AI; Bradshaw TD; Moses JE
Org Biomol Chem; 2016 Aug; 14(31):7585-93. PubMed ID: 27443386
[TBL] [Abstract][Full Text] [Related]
23. Argyrin B, a non-competitive inhibitor of the human immunoproteasome exhibiting preference for β1i.
Allardyce DJ; Bell CM; Loizidou EZ
Chem Biol Drug Des; 2019 Aug; 94(2):1556-1567. PubMed ID: 31074944
[TBL] [Abstract][Full Text] [Related]
24. New Insights into the Function of the Immunoproteasome in Immune and Nonimmune Cells.
Kimura H; Caturegli P; Takahashi M; Suzuki K
J Immunol Res; 2015; 2015():541984. PubMed ID: 26636107
[TBL] [Abstract][Full Text] [Related]
25. Immunoproteasome-specific inhibitors and their application.
Basler M; Groettrup M
Methods Mol Biol; 2012; 832():391-401. PubMed ID: 22350900
[TBL] [Abstract][Full Text] [Related]
26. Structure of human immunoproteasome with a reversible and noncompetitive inhibitor that selectively inhibits activated lymphocytes.
Santos RLA; Bai L; Singh PK; Murakami N; Fan H; Zhan W; Zhu Y; Jiang X; Zhang K; Assker JP; Nathan CF; Li H; Azzi J; Lin G
Nat Commun; 2017 Nov; 8(1):1692. PubMed ID: 29167449
[TBL] [Abstract][Full Text] [Related]
27. Piperlongumine, a potent anticancer phytotherapeutic: Perspectives on contemporary status and future possibilities as an anticancer agent.
Tripathi SK; Biswal BK
Pharmacol Res; 2020 Jun; 156():104772. PubMed ID: 32283222
[TBL] [Abstract][Full Text] [Related]
28. Piperlongumine inhibits the proliferation and survival of B-cell acute lymphoblastic leukemia cell lines irrespective of glucocorticoid resistance.
Han SS; Han S; Kamberos NL
Biochem Biophys Res Commun; 2014 Sep; 452(3):669-75. PubMed ID: 25193702
[TBL] [Abstract][Full Text] [Related]
29. Selective killing of cancer cells by a small molecule targeting the stress response to ROS.
Raj L; Ide T; Gurkar AU; Foley M; Schenone M; Li X; Tolliday NJ; Golub TR; Carr SA; Shamji AF; Stern AM; Mandinova A; Schreiber SL; Lee SW
Nature; 2011 Jul; 475(7355):231-4. PubMed ID: 21753854
[TBL] [Abstract][Full Text] [Related]
30. Bioinformatic analysis of functional differences between the immunoproteasome and the constitutive proteasome.
Kesmir C; van Noort V; de Boer RJ; Hogeweg P
Immunogenetics; 2003 Oct; 55(7):437-49. PubMed ID: 12955356
[TBL] [Abstract][Full Text] [Related]
31. The immunoproteasome: an emerging therapeutic target.
Lee W; Kim KB
Curr Top Med Chem; 2011 Dec; 11(23):2923-30. PubMed ID: 21824107
[TBL] [Abstract][Full Text] [Related]
32. Piperlongumine B and analogs are promising and selective inhibitors for acetylcholinesterase.
Wiemann J; Karasch J; Loesche A; Heller L; Brandt W; Csuk R
Eur J Med Chem; 2017 Oct; 139():222-231. PubMed ID: 28802122
[TBL] [Abstract][Full Text] [Related]
33. Identification of novel ROS inducer by merging the fragments of piperlongumine and dicoumarol.
Xu X; Fang X; Wang J; Zhu H
Bioorg Med Chem Lett; 2017 Mar; 27(5):1325-1328. PubMed ID: 28159415
[TBL] [Abstract][Full Text] [Related]
34. Bisbenzimidazole derivatives as potent inhibitors of the trypsin-like sites of the immunoproteasome core particle.
Koroleva ON; Pham TH; Bouvier D; Dufau L; Qin L; Reboud-Ravaux M; Ivanov AA; Zhuze AL; Gromova ES; Bouvier-Durand M
Biochimie; 2015 Jan; 108():94-100. PubMed ID: 25446655
[TBL] [Abstract][Full Text] [Related]
35. Auranofin induces apoptosis by ROS-mediated ER stress and mitochondrial dysfunction and displayed synergistic lethality with piperlongumine in gastric cancer.
Zou P; Chen M; Ji J; Chen W; Chen X; Ying S; Zhang J; Zhang Z; Liu Z; Yang S; Liang G
Oncotarget; 2015 Nov; 6(34):36505-21. PubMed ID: 26431378
[TBL] [Abstract][Full Text] [Related]
36. Piperlongumine induces apoptotic and autophagic death of the primary myeloid leukemia cells from patients via activation of ROS-p38/JNK pathways.
Xiong XX; Liu JM; Qiu XY; Pan F; Yu SB; Chen XQ
Acta Pharmacol Sin; 2015 Mar; 36(3):362-74. PubMed ID: 25619389
[TBL] [Abstract][Full Text] [Related]
37. Piperlongumine (piplartine) as a lead compound for anticancer agents - Synthesis and properties of analogues: A mini-review.
Piska K; Gunia-Krzyżak A; Koczurkiewicz P; Wójcik-Pszczoła K; Pękala E
Eur J Med Chem; 2018 Aug; 156():13-20. PubMed ID: 30006159
[TBL] [Abstract][Full Text] [Related]
38. Piperlongumine induces ROS mediated apoptosis by transcriptional regulation of SMAD4/P21/P53 genes and synergizes with doxorubicin in osteosarcoma cells.
Rawat L; Nayak V
Chem Biol Interact; 2022 Feb; 354():109832. PubMed ID: 35085581
[TBL] [Abstract][Full Text] [Related]
39. Emerging role of immunoproteasomes in pathophysiology.
Kaur G; Batra S
Immunol Cell Biol; 2016 Oct; 94(9):812-820. PubMed ID: 27192937
[TBL] [Abstract][Full Text] [Related]
40. Piperlongumine and immune cytokine TRAIL synergize to promote tumor death.
Li J; Sharkey CC; King MR
Sci Rep; 2015 May; 5():9987. PubMed ID: 25984950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
